Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene TherapeuticsENGN -2.05%12 EV-to-EBITDA is 0.79 as of Aug. 28, 2026. GuruFocus rates ENGN with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 414 Biotechnology companies, enGene Therapeutics ranks better than 83.82% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, enGene Therapeutics's enterprise value is $-97.17 Mil.
enGene Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 was $-123.45 Mil. Therefore, enGene Therapeutics's EV-to-EBITDA for today is 0.79.
The historical rank and industry rank for enGene Therapeutics's EV-to-EBITDA or its related term are showing as below:
ENGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.79
Current: 0.79
During the past 6 years, the highest EV-to-EBITDA of enGene Therapeutics was 0.79. The lowest was 0.00. And the median was 0.00.
ENGN's EV-to-EBITDA is ranked better than 83.82% of 414
companies
in the Biotechnology industry
Industry Median: 13.55
vs ENGN: 0.79
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
enGene Therapeutics's PE Ratio (TTM) for today is calculated as:
enGene Therapeutics's share price for today is $1.91.
enGene Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.170.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for enGene Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, enGene Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Therapeutics EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where enGene Therapeutics's EV-to-EBITDA falls into.
enGene Therapeutics's current Enterprise Value is $-97.17 Mil.
enGene Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-123.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Therapeutics (ENGN) has a EV-to-EBITDA of 0.79 as of Aug. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on enGene Therapeutics. According to the industry distribution chart, enGene Therapeutics ranks #67 out of 414 companies in the Biotechnology industry, placing it in the top 16.2%.
Is enGene Therapeutics' EV-to-EBITDA too high?
enGene Therapeutics' current EV-to-EBITDA is 0.79. The Biotechnology industry median EV-to-EBITDA is 13.55. enGene Therapeutics' value of 0.79 is 94.2% below this industry median. Based on the distribution chart, enGene Therapeutics ranks #67 out of 414 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, enGene Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' EV-to-EBITDA compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #67 out of 414 companies for EV-to-EBITDA. This places enGene Therapeutics in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.55. enGene Therapeutics' value of 0.79 is 94.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.55, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. enGene Therapeutics's current EV-to-EBITDA of 0.79 is 94.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on enGene Therapeutics. For the Biotechnology industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enGene Therapeutics's current EV-to-EBITDA is 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (ENGN) has a current EV-to-EBITDA of 0.79. The current EV-to-EBITDA is 0.79 and 94.2% below the Biotechnology industry median of 13.55. enGene Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For enGene Therapeutics (ENGN), the current EV-to-EBITDA is 0.79 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
12GF Score
Get the complete analysis for ENGN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENGN has been successfully added to your 
